CGEM [NASD]
Cullinan Oncology, Inc.
Index- P/E5.20 EPS (ttm)2.19 Insider Own1.00% Shs Outstand45.61M Perf Week-3.44%
Market Cap453.72M Forward P/E- EPS next Y-2.99 Insider Trans-1.97% Shs Float37.68M Perf Month3.40%
Income105.50M PEG- EPS next Q-0.67 Inst Own82.30% Short Float / Ratio5.67% / 15.34 Perf Quarter-9.65%
Sales0.00M P/S- EPS this Y-21.70% Inst Trans-1.63% Short Interest2.14M Perf Half Y-22.11%
Book/sh12.85 P/B0.89 EPS next Y-228.30% ROA19.50% Target Price28.50 Perf Year-14.85%
Cash/sh14.47 P/C0.79 EPS next 5Y- ROE20.70% 52W Range7.30 - 15.89 Perf YTD6.54%
Dividend- P/FCF- EPS past 5Y- ROI-16.00% 52W High-29.26% Beta-
Dividend %- Quick Ratio21.50 Sales past 5Y- Gross Margin- 52W Low53.97% ATR0.55
Employees40 Current Ratio21.50 Sales Q/Q- Oper. Margin- RSI (14)50.91 Volatility4.40% 5.39%
OptionableYes Debt/Eq0.00 EPS Q/Q-36.20% Profit Margin- Rel Volume0.55 Prev Close11.40
ShortableYes LT Debt/Eq0.00 Earnings- Payout0.00% Avg Volume139.16K Price11.24
Recom1.50 SMA202.00% SMA50-0.02% SMA200-8.03% Volume38,205 Change-1.40%
Nov-21-22Initiated BTIG Research Buy $20
Apr-27-21Upgrade Morgan Stanley Equal-Weight → Overweight $40
Feb-02-21Initiated SVB Leerink Outperform $52
Feb-02-21Initiated Morgan Stanley Equal-Weight $38
Feb-02-21Initiated Evercore ISI Outperform $55
Feb-01-21Initiated H.C. Wainwright Buy $47
Feb-02-23 04:01PM
Feb-01-23 04:42PM
Jan-24-23 08:00AM
Jan-23-23 11:07AM
Jan-03-23 05:13PM
10:31PM Loading…
Dec-28-22 10:31PM
Dec-02-22 05:00PM
Nov-14-22 07:00AM
Nov-02-22 08:00AM
Nov-01-22 05:23PM
07:00AM
Oct-25-22 07:00AM
Oct-03-22 04:50PM
Sep-07-22 08:00AM
Sep-01-22 05:27PM
04:57PM Loading…
Aug-15-22 04:57PM
Aug-10-22 07:00AM
Aug-01-22 04:55PM
08:00AM
Jul-29-22 05:00AM
05:00AM
Jul-05-22 04:01PM
Jul-01-22 04:37PM
Jun-23-22 08:00AM
Jun-01-22 05:00PM
May-31-22 08:00AM
May-26-22 08:45AM
May-19-22 08:00AM
May-16-22 06:45AM
May-12-22 11:18AM
02:00AM Loading…
02:00AM
May-08-22 09:23AM
May-02-22 05:00PM
Apr-27-22 10:00AM
Apr-05-22 08:00AM
Apr-04-22 04:34PM
Mar-29-22 07:54AM
Mar-28-22 04:01PM
Mar-17-22 07:08AM
07:00AM
Mar-09-22 08:00AM
Mar-08-22 05:30PM
Feb-28-22 08:00AM
Feb-12-22 06:50AM
Feb-07-22 06:30AM
Jan-10-22 06:30AM
Jan-05-22 09:00AM
Jan-04-22 07:34AM
07:00AM
Dec-16-21 01:04PM
06:30AM
Dec-13-21 07:00AM
Nov-22-21 12:37PM
Nov-14-21 07:04AM
Nov-09-21 06:45AM
Oct-29-21 11:47AM
Oct-18-21 07:00AM
Sep-08-21 04:01PM
Aug-16-21 06:44AM
Aug-10-21 06:30AM
Aug-05-21 04:05PM
Jul-19-21 07:56PM
Jun-29-21 08:00AM
Jun-07-21 10:57AM
09:26AM
08:30AM
Jun-04-21 11:53AM
09:00AM
May-21-21 08:00AM
May-19-21 05:00PM
May-14-21 06:30AM
Apr-08-21 01:38AM
Apr-07-21 10:08AM
Mar-30-21 06:15AM
Mar-02-21 09:48AM
Feb-22-21 07:30AM
Jan-12-21 09:43PM
Jan-08-21 12:13AM
Jan-07-21 09:03PM
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Michaelson JenniferSee RemarksNov 25Option Exercise4.304,00017,20057,031Nov 29 04:05 PM
Michaelson JenniferSee RemarksNov 25Sale13.304,00053,20053,031Nov 29 04:05 PM
Michaelson JenniferSee RemarksSep 27Option Exercise4.304,00017,20057,031Sep 29 04:05 PM
Michaelson JenniferSee RemarksSep 27Sale12.404,00049,60053,031Sep 29 04:05 PM
F2 Vision SCS10% OwnerAug 04Sale14.3125,989371,7881,255,963Aug 04 09:01 PM
F2 Vision SCS10% OwnerAug 03Sale14.2419,129272,3341,281,952Aug 04 09:01 PM
F2 Vision SCS10% OwnerAug 02Sale14.104,79267,5541,301,081Aug 04 09:01 PM
Michaelson JenniferChief Development OfficerJul 25Option Exercise4.308,00034,40061,031Jul 26 05:44 PM
Michaelson JenniferChief Development OfficerJul 25Sale14.518,000116,08053,031Jul 26 05:44 PM
Savill CorrineActing Chief Business OfficerJul 19Sale15.2214,958227,661149,615Jul 21 04:30 PM
Savill CorrineActing Chief Business OfficerJul 18Sale15.065,04275,933164,573Jul 21 04:30 PM
Savill CorrineActing Chief Business OfficerJul 11Sale13.3340,000533,304169,615Jul 12 04:14 PM
Jovan-Embiricos Morana10% OwnerJun 24Option Exercise4.30140,374603,608252,881Jun 28 09:24 PM
F2 Bioscience I 2017 Ltd10% OwnerJun 23Sale13.0029,631385,310537,392Jun 23 06:47 PM
F2 Bioscience I 2017 Ltd10% OwnerJun 22Sale12.7049,953634,578567,023Jun 23 06:47 PM
F2 Bioscience I 2017 Ltd10% OwnerJun 21Sale12.7722,319284,929616,976Jun 23 06:47 PM
AHMED NADIMPresident and CEOJun 06Buy12.408,090100,3168,090Jun 07 04:33 PM
BVF PARTNERS L P/IL10% OwnerJun 01Buy11.00751,3968,264,9054,058,854Jun 03 06:24 PM
F2 Vision SCS10% OwnerMay 16Sale11.2335,158394,8281,305,873May 16 08:54 PM
BVF PARTNERS L P/IL10% OwnerMay 13Buy9.13109,9001,003,9363,653,213May 16 07:34 PM
F2 Vision SCS10% OwnerMay 13Sale10.11119,5081,208,3771,341,031May 16 08:54 PM
BVF PARTNERS L P/IL10% OwnerMay 12Buy9.061,000,0009,060,0003,599,615May 16 07:34 PM
F2 Vision SCS10% OwnerMay 12Sale9.25264,0722,442,5871,460,539May 16 08:54 PM
BVF PARTNERS L P/IL10% OwnerApr 01Buy10.75276,0002,966,9723,056,616Apr 05 06:45 PM